Lintzeris N, Clark N, Winstock A, Dunlop A, Muhleisen P, Gowing L, Ali R, Ritter A, Bell J, Quigley A, Mattick RP, Monheit B, White J
Canberra
Report
National Drug Strategy
Buprenorphine is registered in Australia for the management of opioid dependence within a framework of medical, social and psychological treatment. Buprenorphine is indicated for use in detoxification and maintenance treatment of opioid dependence. To assist in the safe and effective provision of buprenorphine treatment in Australia, these national guidelines were commissioned by the Commonwealth Department of Health and Ageing under the auspices of the National Expert Advisory Committee on Illicit Drugs (NEACID).
Lintzeris N, Clark N, Winstock A, Dunlop A, Muhleisen P, Gowing L, Ali R, Ritter A, Bell J, Quigley A, Mattick RP, Monheit B, White J. abstract